Salix Pharmaceuticals, Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Salix Pharmaceuticals, Ltd. - overview
Location
Raleigh, NC, US
Primary Industry
Pharmaceuticals
About
Salix Pharmaceuticals, Ltd. is a company focused on developing and commercializing treatments for gastrointestinal disorders, providing effective solutions for patients suffering from conditions like irritable bowel syndrome and chronic constipation. Founded by Lorin Johnson, Salix Pharmaceuticals, Ltd. operates out of Raleigh, US, and specializes in products for gastrointestinal disorders.
The company has not undergone any significant business strategy changes or pivots since its establishment. Currently, the CEO is Carolyn Logan. Salix Pharmaceuticals specializes in developing and commercializing innovative treatments for gastrointestinal (GI) disorders. Their core product offerings address a wide range of GI conditions, including irritable bowel syndrome (IBS), chronic constipation, and other related ailments.
These products are designed to alleviate symptoms, improve patient quality of life, and fill therapeutic gaps in the market. The company’s client base primarily consists of healthcare professionals, including gastroenterologists and primary care physicians, who prescribe these medications to patients seeking effective treatment options. Salix's products are marketed in key geographical regions, including the United States, where they have established a significant presence in the specialty pharmaceutical sector. Salix Pharmaceuticals generates revenue through a multi-faceted business model that encompasses B2B and direct-to-consumer transactions.
The company engages in partnerships with healthcare providers and pharmaceutical distributors, facilitating the distribution of its products to pharmacies and medical facilities. Their revenue structure includes prescription medications that are reimbursed through insurance plans, creating a pathway for consistent cash flow from healthcare systems. Specific pricing plans for their flagship products are tailored to meet market demands while ensuring accessibility for patients. Salix’s commitment to advancing GI healthcare drives its revenue growth, supported by a robust pipeline of innovative treatments and a focus on patient-centric solutions.
Primary Industry
Pharmaceuticals
Sub Industries
Specialty Pharmaceuticals, Pharmaceutical Research & Development
Website
www.salix.com
Total Amount Raised
Subscriber access only
Salix Pharmaceuticals, Ltd. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Trade Sale | Completed | Oceana Therapeutics | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.